Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 11, 2020 8:49am
144 Views
Post# 32087008

RE:RE:COVID ... BioPUB ...

RE:RE:COVID ... BioPUB ...
Doccole wrote:

Finally saw BioPub.  Good direction.  H2s was surprising.  January/February sounds like a uplisting.  

Going to add more, sell some when it doubles from here and ride out the balance until completion or major partnership. 

I'm waiting for a billion in cash, and a market cap of 200m, lol.  Ready 21 



I see ATE getting back into negotiations after Christmas and that continues until they are done - whenever that may be.
I see the comprehensive corporate update just before J.P.Morgan ... around January 10th.
Going into J.P.Morgan, we start seeing some bigger buying activity, as the corporate update excites institutions.
Then we are heavy into Phase 3 countdown, with End-of-Phase2 meeting and the NDA filing.
This brings excitement along with investors piling in.
It is during this time that ATE monitors the share price and decided the right moment to jump to a US exchange.  The price has to be right ... or no jump.
I think we're all betting on there being a jump.

The key - the glue - will be the quality of the information, including the comprehensive corporate update.  Will it excite?  Then there's the matter of the animal studies and how/if those results start to trickle out - maybe it only comes out in the corporate update ???  Will see. 

Lots of unknowns but many ways to excite investors.  
<< Previous
Bullboard Posts
Next >>